论文部分内容阅读
近年肝纤维化的血清学诊断已开始应用于临床。我们用放免法测定了正常人及急慢性肝病病人血清ＰＣⅢ含量共１２０例（急性肝炎２５例，慢迁肝１７例，慢活肝２０例，肝硬化２６例，肝癌８例，正常对照２４例），结果：肝硬化病人血清ＰＣⅢ含量明显增高，为正常对照组的３倍（２６３．７±３９．８４μｇ／Ｌ与９１．４４±１６．５２μｇ／Ｌ），慢活肝及肝癌亦明显增高。含量分布图显示此三组病例与正常对照组及慢迁肝组均无重叠，以肝硬化组更为明显。而且血清ＰＣⅢ与转氨酶、白蛋白、及胆红素等指标不相关。结果表明血清ＰＣⅢ测定可作为诊断肝纤维化的一个重要指标。
In recent years, serological diagnosis of liver fibrosis has begun to be used clinically. We used radioimmunoassay to determine the serum levels of PCⅢ in normal and acute and chronic liver disease patients (120 cases of acute hepatitis, 17 cases of slow-moving liver, 20 cases of slow-living liver, 26 cases of liver cirrhosis, 8 cases of liver cancer and 24 cases of normal control ). Results: The serum levels of PCⅢ in patients with cirrhosis were significantly higher than those in normal controls (263.7 ± 39.84μg / L vs 91.44 ± 16.52μg / L), and were also significantly higher in patients with liver cirrhosis and liver cancer . Content distribution map shows that these three groups of patients and normal control group and slow liver group did not overlap, with cirrhosis more obvious. And serum PC Ⅲ and aminotransferase, albumin, and bilirubin and other indicators are not related. The results show that serum PC Ⅲ determination can be used as an important indicator of diagnosis of liver fibrosis.